Bevacizumab is a recombinant humanized monoclonal antibody against VEGF and is widely used in the treatment of lung cancer, either in monotherapy or in combination with chemotherapy or immunotherapy [39, 40]. The gene discussed is VEGFA; the disease is lung cancer.